CAS 146464-95-1

Pralatrexate

Description:

Pralatrexate is a synthetic antifolate compound primarily used in the treatment of certain types of cancer, particularly peripheral T-cell lymphoma. It functions as an inhibitor of dihydrofolate reductase, an enzyme critical for DNA synthesis and cell proliferation. This mechanism disrupts the folate metabolism in rapidly dividing cancer cells, leading to their growth inhibition. Pralatrexate is characterized by its high affinity for the reduced folate carrier, which facilitates its uptake into cells. The compound is typically administered via intravenous injection and is known for its ability to penetrate tissues effectively. Its chemical structure includes a pteridine core, which is essential for its biological activity. Pralatrexate has been associated with various side effects, including myelosuppression, mucositis, and fatigue, necessitating careful monitoring during treatment. Overall, pralatrexate represents a targeted therapeutic approach in oncology, leveraging its biochemical properties to combat malignancies that are resistant to conventional therapies.

Formula: C₂₃H₂₃N₇O₅

InChI: InChI=1S/C23H23N7O5/c1-2-3-14(10-15-11-26-20-18(27-15)19(24)29-23(25)30-20)12-4-6-13(7-5-12)21(33)28-16(22(34)35)8-9-17(31)32/h1,4-7,11,14,16H,3,8-10H2,(H,28,33)(H,31,32)(H,34,35)(H4,24,25,26,29,30)/t14?,16-/m0/s1

InChI key: InChIKey=OGSBUKJUDHAQEA-WMCAAGNKSA-N

SMILES: NC=1C2=C(N=CC(CC(CC#C)C3=CC=C(C(N[C@@H](CCC(O)=O)C(O)=O)=O)C=C3)=N2)N=C(N)N1

Synonyms:

• <span class="text-smallcaps">L</span>-Glutamic acid, N-[4-[1-[(2,4-diamino-6-pteridinyl)methyl]-3-butyn-1-yl]benzoyl]-
• <span class="text-smallcaps">L</span>-Glutamic acid, N-[4-[1-[(2,4-diamino-6-pteridinyl)methyl]-3-butynyl]benzoyl]-
• Folotyn
• N-(4-(1-((2,4-Diamino-6-pteridinyl)methyl)-3-butynyl)benzoyl)-L-glutamic acid
• N-[4-[1-[(2,4-Diamino-6-pteridinyl)methyl]-3-butyn-1-yl]benzoyl]-<span class="text-smallcaps">L</span>-glutamic acid
• N-{4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl}-L-glutamic acid
• NSC 754230
• Pralatrexate
• L-Glutamic acid, N-[4-[1-[(2,4-diamino-6-pteridinyl)methyl]-3-butynyl]benzoyl]-
• N-[4-[1-[(2,4-Diamino-6-pteridinyl)methyl]-3-butyn-1-yl]benzoyl]-L-glutamic acid
• 10-Propargyl-10-deazaaminopterin
• L-Glutamic acid, N-[4-[1-[(2,4-diamino-6-pteridinyl)methyl]-3-butyn-1-yl]benzoyl]-

L-Glutamic acid, N-[4-[1-[(2,4-diamino-6-pteridinyl)methyl]-3-butyn-1-yl]benzoyl]-

CAS: 146464-95-1

Formula: C₂₃H₂₃N₇O₅

Purity: 98%

Color and Shape: Solid

Molecular weight: 477.4726

Ref: IN-DA001E2I

Pralatrexate

CAS: 146464-95-1

Formula: C₂₃H₂₃N₇O₅

Molecular weight: 477.47

Ref: 7W-GP2890

Pralatrexate

CAS: 146464-95-1

Pralatrexate

Purity: ≥90%

Molecular weight: 477.47g/mol

Ref: 54-BUP08501

(2S)-2-(4-(1-(2,4-Diaminopteridin-6-yl)Pent-4-yn-2-yl)Benzamido)Pentanedioic Acid

CAS: 146464-95-1

(2S)-2-(4-(1-(2,4-Diaminopteridin-6-yl)Pent-4-yn-2-yl)Benzamido)Pentanedioic Acid

Purity: 98%

Molecular weight: 477.47g/mol

Ref: 54-OR1023062

Pralatrexate-13C5-15N

CAS: 146464-95-1

Formula: C₁₈₁₃C₅H₂₃N₆₁₅NO₅

Color and Shape: Pale Yellow Solid

Molecular weight: 483.44

Ref: 4Z-P-197002

Pralatrexate

CAS: 146464-95-1

Pralatrexate (10-Propargyl-10-deazaaminopterin) is a folate analogue inhibitor of dihydrofolate reductase (DHFR) exhibiting high affinity for reduced folate

Formula: C₂₃H₂₃N₇O₅

Purity: 94.32% - 99.59%

Color and Shape: Solid

Molecular weight: 477.47

Ref: TM-T6120

Pralatrexate

CAS: 146464-95-1

Formula: C₂₃H₂₃N₇O₅

Molecular weight: 477.48

Ref: 4Z-P-197001

Pralatrexate

CAS: 146464-95-1

Pralatrexate is a drug that belongs to a group of drugs called DNA-damaging agents. It is used for the treatment of t-cell lymphomas and has been shown to be effective in vitro and in vivo. Pralatrexate is a prodrug that undergoes enzymatic conversion to form a phosphoramide mustard, which induces DNA damage by inhibiting DNA synthesis and repair. Pralatrexate has minimal toxicity and does not cross the blood-brain barrier or cause bone marrow suppression, making it an attractive agent for the treatment of t-cell lymphomas.

Formula: C₂₃H₂₃N₇O₅

Purity: Min. 95%

Color and Shape: Powder

Molecular weight: 477.47 g/mol

Ref: 3D-FP159010

L-Glutamic acid, N-[4-[1-[(2,4-diamino-6-pteridinyl)methyl]-3-butyn-1-yl]benzoyl]-

CAS: 146464-95-1

Purity: 98%

Molecular weight: 477.4809875

Ref: 10-F861843

Pralatrexate-13C5

Controlled Product

CAS: 146464-95-1

Applications Pralatrexate-15C5 is labelled Pralatrexate (P700500) which is an antifolate with high affinity for the reduced folate carrier-type 1 that produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma.
References Krug, L.M. et al.: Clin. Cancer Res., 6, 3493 (2000); O'Connor, O.A. et al.: Br. J. Haematol., 139, 425 (2007); O'Connor, O.A. et al.: J. Clin. Oncol., 29, 1182 (2011)

Formula: C₁₈₁₃C₅H₂₃N₇O₅

Color and Shape: Neat

Molecular weight: 492.472

Ref: TR-P700502

Pralatrexate

CAS: 146464-95-1

Formula: C₂₃H₂₃N₇O₅

Molecular weight: 477.48

Ref: ST-EA-CP-P117000